Have a feature idea you'd love to see implemented?
Let us know!

- Stocks
- Healthcare
- NASDAQ: BCYC

Price (delayed)

$24.58

Market cap

$1.7B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.78

Enterprise value

$772.13M

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short

BICYCLE THERAPEUTICS's quick ratio has surged by 163% YoY and by 45% QoQ

BCYC's equity has surged by 145% since the previous quarter

BICYCLE THERAPEUTICS's gross profit has surged by 76% YoY but it has decreased by 4.9% QoQ

BCYC's revenue has soared by 76% YoY but it is down by 4.9% QoQ

BCYC's net income is down by 18% YoY

What are the main financial stats of BCYC

Market
Valuations
Earnings

Shares outstanding

68.99M

Market cap

$1.7B

Enterprise value

$772.13M

Price to earnings (P/E)

N/A

Price to book (P/B)

1.2

Price to sales (P/S)

32.29

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

19.51

Revenue

$39.57M

EBIT

-$159.74M

EBITDA

-$153.09M

Free cash flow

-$164.79M

Per share
Balance sheet
Liquidity

EPS

-$3.78

Free cash flow per share

-$3.17

Book value per share

$20.43

Revenue per share

$0.76

TBVPS

$20.34

Total assets

$1.06B

Total liabilities

$183.54M

Debt

$37.64M

Equity

$873.81M

Working capital

$958.65M

Debt to equity

0.04

Current ratio

14.77

Quick ratio

14.48

Net debt/EBITDA

6.03

Margins
Efficiency
Dividend

EBITDA margin

-386.9%

Gross margin

100%

Net margin

-417.9%

Operating margin

-463.4%

Return on assets

-23.3%

Return on equity

-32.8%

Return on invested capital

-289.3%

Return on capital employed

-16.2%

Return on sales

-403.6%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the BICYCLE THERAPEUTICS stock price performed over time

Intraday

4.46%

1 week

8.95%

1 month

-6.75%

1 year

14.22%

YTD

35.95%

QTD

8.62%

How have BICYCLE THERAPEUTICS's revenue and profit performed over time

Revenue

$39.57M

Gross profit

$39.57M

Operating income

-$183.4M

Net income

-$165.37M

Gross margin

100%

Net margin

-417.9%

BICYCLE THERAPEUTICS's gross profit has surged by 76% YoY but it has decreased by 4.9% QoQ

BCYC's revenue has soared by 76% YoY but it is down by 4.9% QoQ

BCYC's net margin is up by 33% year-on-year but it is down by 3.4% since the previous quarter

The operating margin has grown by 29% YoY but it has contracted by 7% from the previous quarter

What is BICYCLE THERAPEUTICS's growth rate over time

What is BICYCLE THERAPEUTICS stock price valuation

P/E

N/A

P/B

1.2

P/S

32.29

EV/EBIT

N/A

EV/EBITDA

N/A

EV/Sales

19.51

BICYCLE THERAPEUTICS's EPS has increased by 19% YoY and by 14% from the previous quarter

BCYC's equity has surged by 145% since the previous quarter

The stock's P/B is 64% below its 5-year quarterly average of 3.3 and 40% below its last 4 quarters average of 2.0

BCYC's revenue has soared by 76% YoY but it is down by 4.9% QoQ

The P/S is 31% less than the 5-year quarterly average of 46.9 but 20% more than the last 4 quarters average of 27.0

How efficient is BICYCLE THERAPEUTICS business performance

The company's return on invested capital has shrunk by 70% YoY and by 7% QoQ

The ROE has grown by 40% YoY and by 33% from the previous quarter

BICYCLE THERAPEUTICS's ROS has increased by 34% YoY but it has decreased by 2.9% from the previous quarter

The ROA has grown by 29% YoY and by 23% from the previous quarter

What is BCYC's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for BCYC.

How did BICYCLE THERAPEUTICS financials performed over time

BICYCLE THERAPEUTICS's quick ratio has surged by 163% YoY and by 45% QoQ

BCYC's current ratio has surged by 161% year-on-year and by 42% since the previous quarter

BCYC's debt is 96% smaller than its equity

BCYC's equity has surged by 145% since the previous quarter

BICYCLE THERAPEUTICS's debt to equity has plunged by 79% YoY and by 64% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.